US equities |
MU $1,086.40 ▲+3.91% NVDA $237.82 ▼-0.59% SNDK $1,694.88 ▲+2.07% SPCX $167.39 ▼-2.63% AMD $646.60 ▼-0.43% TSLA $378.10 ▼-0.68% INTC $113.04 ▲+0.48% AAPL $336.57 ▲+0.88%
FinancialContent

Betterlife Pharma Inc (CSE:BETR)

0.2700 +0.0050 (+1.89%)
Delayed Quote Updated: 2:46 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Betterlife Pharma Inc

< Previous 1 2 Next >
News headline image
BetterLife Pharma Provides Scientific Update on Neuroplastogenic Activity of BETR-001
From BetterLife Pharma Inc.
Via GlobeNewswire
News headline image
BetterLife Provides Comments on CEO’s Share Position Ownership and Recent BCSC Press Release
From BetterLife Pharma Inc.
Via GlobeNewswire
News headline image
BetterLife Pharma Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric Disorders
From BetterLife Pharma Inc.
Via GlobeNewswire
News headline image
BetterLife Announces Debt Settlements
From BetterLife Pharma Inc.
Via GlobeNewswire
News headline image
Microcap Stocks to Watch: STSS, AGMH, FMTO, SUNE, Signal Strength Amid Market Volatility – More Picks Inside
Via AB Newswire
Topics Artificial Intelligence
News headline image
BetterLife Pharma Appoints Corporate Advisor
From BetterLife Pharma Inc.
Via GlobeNewswire
News headline image
BetterLife Pharma Appoints New Director
From BetterLife Pharma Inc.
Via GlobeNewswire
News headline image
BetterLife Announces Debt Conversions
From BetterLife Pharma Inc.
Via GlobeNewswire
News headline image
USPTO Grants BetterLife’s BETR-001 Composition of Matter Patent
From BetterLife Pharma Inc.
Via GlobeNewswire
News headline image
BetterLife Announces Favorable Outcome in New York Legal Claims
From BetterLife Pharma Inc.
Via GlobeNewswire
News headline image
BetterLife Obtains Favourable Cardiac Safety Data for BETR-001
From BetterLife Pharma Inc.
Via GlobeNewswire
News headline image
BetterLife Obtains Favourable Genotoxicity Data for Oral BETR-001
From BetterLife Pharma Inc.
Via GlobeNewswire
News headline image
BetterLife Announces Fully Subscribed Private Placement Financing
From BetterLife Pharma Inc.
Via GlobeNewswire
News headline image
BetterLife Highlights Advantages of Non-hallucinogenic LSD Derivative BETR-001 and Publication of its Methods to Treat Mood Disorders Patent
From BetterLife Pharma Inc.
Via GlobeNewswire
News headline image
BetterLife Announces Closing of a Private Placement
From BetterLife Pharma Inc.
Via GlobeNewswire
News headline image
BetterLife To Present BETR-001 Preclinical Data at the 2024 Conference of the Federation of European Neuroscience Societies (FENS) in Vienna, Austria
From BetterLife Pharma Inc.
Via GlobeNewswire
News headline image
BetterLife Announces Closing of a Private Placement
From BetterLife Pharma Inc.
Via GlobeNewswire
News headline image
BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001
From BetterLife Pharma Inc.
Via GlobeNewswire
News headline image
BetterLife Announces Intent to Complete Private Placement of Units
From BetterLife Pharma Inc.
Via GlobeNewswire
News headline image
BetterLife Advances BETR-001 IND-enabling Studies
From BetterLife Pharma Inc.
Via GlobeNewswire
News headline image
BetterLife To Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
From BetterLife Pharma Inc.
Via GlobeNewswire
News headline image
BetterLife Announces Closing of $1.168 Million Convertible Debentures to Further Advance IND-enabling Studies of its Non-hallucinogenic LSD-based Drug Candidate BETR-001
From BetterLife Pharma Inc.
Via GlobeNewswire
News headline image
BetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001
From BetterLife Pharma Inc.
Via GlobeNewswire
News headline image
BetterLife’s 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University
From BetterLife Pharma Inc.
Via GlobeNewswire
News headline image
BetterLife Announces Closing of a Private Placement
From BetterLife Pharma Inc.
Via GlobeNewswire
News headline image
BetterLife Announces Extension of Warrants
From BetterLife Pharma Inc.
Via GlobeNewswire
News headline image
BetterLife Pharma to Host Investors Update Call on September 18, 2023
From BetterLife Pharma Inc.
Via GlobeNewswire
News headline image
US Patent and Trademark Office Publishes BetterLife’s Comprehensive Patent for BETR-001 and Other LSD Derivatives
From BetterLife Pharma Inc.
Via GlobeNewswire
News headline image
BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001
From BetterLife Pharma Inc.
Via GlobeNewswire
News headline image
BetterLife Highlights BETR-001 Article in Technology Networks Drug Discovery and Announces Closing of a Private Placement
From BetterLife Pharma Inc.
Via GlobeNewswire
< Previous 1 2 Next >